In conclusion, this work demonstrates that there is a limited core molecular response to reduced SMN levels across the different severities of SMA and opens the “field” up for a more targeted approach to SMA treatment with respect to SMA type. Here, SMN1 is linked to proximal spinal muscular atrophy.